Synthetic peptidomimetic; bradykinin B2 receptor antagonist. Prepn: S. Henke et al., DE 3938751; eidem, US 5648333 (1990, 1997 both to Hoechst). In vitro and in vivo pharmacology studies: F. J. Hock et al., Br. J. Pharmacol. 102, 769 (1991) PubMed; K. Wirth et al., ibid. 774 PubMed. Pharmacology and receptor binding studies: N.-E. Rhaleb et al., Eur. J. Pharmacol. 210, 115 (1992) DOI PubMed; M. Félétou et al., ibid. 274, 57 (1995) DOI PubMed; F. Bellucci et al., ibid. 491, 121 (2004) DOI. Metabolism and HPLC determn in synovial fluid: A. P. Bond et al., Agents Actions Suppl. 38, 582 (1992) PubMed. Chiral amino acid analysis: J. Ermer et al., Arch. Pharm. 328, 635 (1995) DOI. Computational conformation analysis: M. Filizola et al., J. Biomol. Struct. Dyn. 15, 639 (1998) PubMed. Clinical effects on bradykinin-induced vasodilation: J. R. Cockcroft et al., Br. J. Clin. Pharmacol. 38, 317 (1994) PubMed. Clinical evaluation in hereditary angioedema: K. Bork et al., J. Allergy Clin. Immunol. 119, 1497 (2007) DOI PubMed.
In treatment of hereditary angioedema.
Bradykinin Antagonist